SHANDONG XINHUA (00719) rises over 10%, the company's A-shares have hit the daily limit. As of the time of writing, it has increased by 10.27%, priced at 6.23 Hong Kong dollars, with a transaction volume of 81.8506 million Hong Kong dollars.
According to the Zhito Finance APP, SHANDONG XINHUA (00719) has risen over 10%, with the company's A shares hitting the limit. As of the time of reporting, the increase is 10.27%, priced at 6.23 HKD, with a trading volume of 81.8506 million HKD.
On the news front, a report from the China CDC indicates that the overall trend of acute respiratory infectious diseases is continuously rising, with the positive rate of influenza viruses having 'jumped to first place.' On January 2, Dingtang Kuaiyao released data showing that sales of pharmaceuticals for respiratory diseases continue to rise sharply. In the past month, sales of the anti-influenza pharmaceutical Oseltamivir and Sufuqida have increased by as much as 164%. At the same time, sales of cold and fever products have also shown significant growth, with common antipyretic patches, for example, experiencing a sales growth rate of 181.5%. It is reported that Shandong Xinhua Pharmaceutical is a major global supplier of antipyretic and analgesic medications, with a product line that includes Ibuprofen, Aspirin, the Wuan series, Meloxicam, and others.
